leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...96979899100101102103104105106...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    OPTIMAL ADJUVANT THERAPY IN PATIENTS WITH BORDERLINE RESECTABLE AND LOCALLY ADVANCED PANCREATIC CANCER WHO HAD RECEIVED NEOADJUVANT FOLFIRINOX (Poster Hall - San Diego Convention Center) -  Apr 25, 2022 - Abstract #DDW2022DDW_4683;    
    In subgroup analysis, 5-fluorouracil-based regimen was associated with less recurrence (HR, 0.35 [95%CI, 0.13–0.93], p = 0.035) and less patients' death (HR, 0.29 [95%CI, 0.09–0.94], p = 0.039) for pathologic responders to neoadjuvant FOLFIRINOX. Conclusion s: 5-FU-based adjuvant therapy seems to be the optimal adjuvant therapy for patients who showed response to neoadjuvant FOLFIRINOX for borderline resectable and locally advanced pancreatic cancer.
  • ||||||||||  PRIMARY SQUAMOUS CELL CARCINOMA OF THE PANCREAS: A COMPARATIVE SURVIVAL ANALYSIS OF A RARE DISEASE WITH A CASE PRESENTATION AND LITERATURE REVIEW (Poster Hall - San Diego Convention Center) -  Apr 25, 2022 - Abstract #DDW2022DDW_4672;    
    The patient was treated with FOLFIRINOX, Gemcitabine and Abraxane and died in 7 months from his cancer.Literature review: Imaging and histological examination differentiates SCC from adenocarcinoma of the pancreas...Regimens include Gemcitabine, Cisplatin, 5-FU, Oxaliplatin and carboplatin and Paclitaxel...There is currently uncertainty about the treatment options including choice of chemotherapy. More clinical and molecular data are needed to improve the prognosis in this malignancy.
  • ||||||||||  Avastin (bevacizumab) / Roche
    NOVEL STRATEGY OF TWO STAGE HEPATECTOMY COMBINED WITH 90Y RADIOEMBOLIZATION FOR MULTIPLE BILOBAR COLORECTAL LIVER METASTASES (Poster Hall - San Diego Convention Center) -  Apr 25, 2022 - Abstract #DDW2022DDW_3526;    
    She underwent laparoscopic left hemicolectomy for primary lesion and received 13 cycle of FOLFOX plus bevacizumab and 10 cycles of FOLFIRI plus bevacizumab...Liver resection can then be safely performed following 90Y radioembolization. Utilization of 90Y radioembolization combined with staged hepatectomies can be useful strategy for multiple bilobar liver metastases.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    EVALUATING THE TRα1-DEPENDENT CHARACTERISTICS OF COLON CANCER STEM CELL BIOLOGY (Poster Hall - San Diego Convention Center) -  Apr 25, 2022 - Abstract #DDW2022DDW_1824;    
    We also gained insights into the T3/TRα1-dependent tumor cell behavior, eventually including their response to chemotherapy. These studies are currently enlarged to mouse models and to human organoids.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    S-ADENOSYLMETHIONINE PROTECTS AGAINST CHEMOTHERAPY INDUCED LIVER INJURY (ePoster - DDW Virtual) -  Apr 25, 2022 - Abstract #DDW2022DDW_902;    
    Methods : C57BL/6 mice (n=6 per group) were treated with vehicle, FOLFOX, or FOLFOX + SAMe weekly (intraperitoneal oxaliplatin 6 mg/kg followed 2 h later by 5-FU 50 mg/kg and folinic acid 90 mg/kg ± SAMe 100mg/kg/day by oral gavage) for 5 weeks...Lack of PAI-1 appears to protect from FOLFOX-induced SOS. Further studies investigating the cell type of origin of PAI-1 associated with FOLFOX induced liver injury is warranted.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    INTERLEUKIN-8 IS A POTENTIAL MEDIATOR OF CHEMOTHERAPY RESPONSE IN PANCREATIC DUCTAL ADENOCARCINOMA (23 - San Diego Convention Center) -  Apr 25, 2022 - Abstract #DDW2022DDW_747;    
    Through longitudinal biospecimen acquisition of PDAC patients, we have discovered a subpopulation of IL8-high tumor epithelial cells which may be important in mediating the highly-therapy resistant tumor microenvironment in this deadly disease. Further function studies are currently underway to investigate the role of IL8 in tumor progression and therapy response.
  • ||||||||||  sirexatamab (DKN-01) / Leap Therap
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  DisTinGuish: A Study of DKN-01 in Combination With Tislelizumab  (clinicaltrials.gov) -  Apr 25, 2022   
    P2a,  N=72, Recruiting, 
    Further function studies are currently underway to investigate the role of IL8 in tumor progression and therapy response. Trial completion date: May 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  oxaliplatin / Generic mfg.
    Enrollment change, Trial completion date, Trial termination:  PIPOX: Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers (clinicaltrials.gov) -  Apr 25, 2022   
    P1/2,  N=34, Terminated, 
    Trial completion date: May 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 N=50 --> 34 | Trial completion date: Jun 2021 --> Oct 2021 | Recruiting --> Terminated; The 34 patients included had all completed their treatment period under the protocol and the data could be collected to assess the main objective and the secondary objectives before the last theoretical follow-up.
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
    Enrollment closed, Enrollment change, Combination therapy, Metastases:  CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Apr 25, 2022   
    P1/2,  N=49, Active, not recruiting, 
    N=50 --> 34 | Trial completion date: Jun 2021 --> Oct 2021 | Recruiting --> Terminated; The 34 patients included had all completed their treatment period under the protocol and the data could be collected to assess the main objective and the secondary objectives before the last theoretical follow-up. Recruiting --> Active, not recruiting | N=33 --> 49
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date:  AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Apr 22, 2022   
    P3,  N=670, Active, not recruiting, 
    While the study was formally negative, it provided a signal to further investigate this combination for the group of patients with previous docetaxel therapy. Trial completion date: Jun 2022 --> Dec 2030
  • ||||||||||  pemetrexed / Generic mfg.
    Review, Journal:  Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. (Pubmed Central) -  Apr 21, 2022   
    There are several experimental options to prevent or manage pemetrexed-related toxicity, such as the use of standard folinic acid, hemodialysis, antidotes such as thymidine, hypoxanthine, and glucarpidase, and the use of therapeutic drug monitoring. These strategies still need clinical evaluation before implementation, but could enable treatment with pemetrexed for patients who are at risk for toxicity, such as in renal impairment.
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
    A RARE CASE OF ESOPHAGEAL ADENOCARCINOMA IN A CHILD () -  Apr 20, 2022 - Abstract #ASPHO2022ASPHO_38;    
    Adding agents that increase the number and function of effector cells may be required for clinical benefit. Esophageal carcinoma is very rare in children, however our patient presented with anemia, a common presentation of this disease in adults.She is being treated with FLOT at multidisciplinary cancer center, with experts from adult oncology.Lastly, given her young presentation, genetic testing was undertaken and p53 mutation likely caused early development of her EAC.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Clinical, Retrospective data, Journal:  Psychomotor development in infants and young children with Down syndrome-A prospective, repeated measure, post-hoc analysis. (Pubmed Central) -  Apr 19, 2022   
    P3
    We carried out repeated measure analysis of the global development quotient (GDQ) and developmental age using data from the Assessment of Systematic Treatment with Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children (ACTHYF) study (NCT01576705)...Future studies should aim at elucidating the mechanisms underlying motor and language development. Early pharmacological interventions together with early childhood therapies might be necessary to improve the developmental trajectory of children with DS.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal, Real-world evidence:  Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis. (Pubmed Central) -  Apr 19, 2022   
    The precise evaluation of the baseline antitumor specific immunity is critical to predict clinical outcome. Whereas efficacy tended to be slightly better in the mFOLFIRINOX group than in the sequential chemotherapy group, given the higher incidence of grade ≥3 adverse events with mFOLFIRINOX than with sequential chemotherapy, sequential chemotherapy is a regimen with better risk-benefit balance than mFOLFIRINOX, and can be considered a second-line treatment option for patients with unresectable pancreatic cancer.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Chemotherapeutic Risk lncRNA-PVT1 SNP Sensitizes Metastatic Colorectal Cancer to FOLFOX Regimen. (Pubmed Central) -  Apr 19, 2022   
    High GSTA2 expression predicted poor clinical outcome in metastatic colorectal cancer treated with FOLFOX. In conclusion, this study provided that PVT1 with rs2278176 T allele altered the binding affinity with hsa-miR-297, leading to decreased GSTA2 expression and sensitized CRC cells to FOLFOX chemotherapy, suggesting rs2278176 CT/TT genotypes might serve as a predictive biomarker to improve prognosis in patients with metastatic CRC treated with FOLFOX.
  • ||||||||||  Trial completion:  A Phase II Study of Neoadjuvant FOLFIRINOX (clinicaltrials.gov) -  Apr 19, 2022   
    P2,  N=48, Completed, 
    In conclusion, this study provided that PVT1 with rs2278176 T allele altered the binding affinity with hsa-miR-297, leading to decreased GSTA2 expression and sensitized CRC cells to FOLFOX chemotherapy, suggesting rs2278176 CT/TT genotypes might serve as a predictive biomarker to improve prognosis in patients with metastatic CRC treated with FOLFOX. Active, not recruiting --> Completed
  • ||||||||||  methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    Preclinical, Journal:  Efficiency of antioxidant Avenanthramide-C on high-dose methotrexate-induced ototoxicity in mice. (Pubmed Central) -  Apr 15, 2022   
    Folinic acid (FA) is a well-known MTX antidote that protects against toxicity caused by the drug and has been used for decades...The antioxidant AVN-C exerts a strong protective effect against MTX-induced ototoxicity and preserved the inner ear structures (synapses, neurons, and OHCs) from MTX-induced damage. The mechanism of AVN-C against MTX suggests that ROS is involved in HDMTX-induced ototoxicity.
  • ||||||||||  lunresertib (RP-6306) / Repare Therap
    Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  MINOTAUR: Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (clinicaltrials.gov) -  Apr 14, 2022   
    P1,  N=104, Recruiting, 
    The mechanism of AVN-C against MTX suggests that ROS is involved in HDMTX-induced ototoxicity. Trial completion date: Dec 2023 --> Dec 2024 | Initiation date: Feb 2022 --> Jun 2022 | Trial primary completion date: Nov 2022 --> Jun 2023